O’Melveny Worldwide

China Business Law Journal: Law Firm Quartet Advises Gaush Meditech’s Hong Kong Listing

December 21, 2022

O’Melveny & Myers LLP advised Gaush Meditech Ltd., the fourth largest ophthalmic medical device company in China, on US law in its recent IPO and listing on the Hong Kong Stock Exchange. Gaush Meditech raised HK$672 million (US$86.34 million) in its listing, offering a total of 13.06 million shares at HK$51.4 per share. The O’Melveny team was led by corporate partners Ke Geng and Ke Zhu.

Read the full article here.